NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of iLearningEngines, Inc. (NASDAQ: AILE) between April 22, 2024 and August 28, 2024, both dates inclusive (the “Class Period”), of the important December 6, 2024 lead plaintiff deadline. SO WHAT: If you purchased iLearningEngines securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ...

NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company’s initial public offering conducted between February 9 and 13, 2024 (the “IPO”), of the important November 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Metagenomi stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bumble Inc. (NASDAQ: BMBL) between November 7, 2023 and August 7, 2024, both dates inclusive (the “Class Period”), of the important November 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Bumble securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, both dates inclusive (the “Class Period”), of the important November 5, 2024 lead plaintiff deadline. SO WHAT: If you purchased Agenus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024, both dates inclusive (the "Class Period"). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 13, 2024. SO WHAT: If you purchased Edwards securities during the C ...

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of iLearningEngines, Inc. (NASDAQ: AILE) between April 22, 2024 and August 28, 2024, both dates inclusive (the “Class Period”), of the important December 6, 2024 lead plaintiff deadline. SO WHAT: If you purchased iLearningEngines securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ...

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company's initial public offering conducted between February 9 and 13, 2024 (the "IPO"), of the important November 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Metagenomi stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

文章核心观点 - 公司Orthofix Medical Inc.的股票在2022年10月11日至2023年9月12日期间存在潜在的欺诈行为 [1][3] - 公司管理层存在重复不当和冒犯性行为 [3] - 当真相被披露时,投资者遭受损失 [3] 公司情况总结 - Orthofix Medical Inc.是一家上市公司,股票代码为NASDAQ: OFIX [1] - 该公司是一家全球性的投资者权利法律公司Rosen Law Firm的客户 [1][2] - Rosen Law Firm在证券集体诉讼和股东衍生诉讼方面有丰富的经验,曾获得最大规模的针对中国公司的证券集体诉讼和和解 [2] - Rosen Law Firm在2017年被ISS Securities Class Action Services评为证券集体诉讼和解数量第一,并在2013年以来连续4年位列前四 [2] - 2019年Rosen Law Firm为投资者赢得了4.38亿美元的赔偿,2020年创始合伙人Laurence Rosen被评为原告律师界的泰坦 [2] 诉讼进展 - 该集体诉讼已经提起,投资者可以在2024年10月21日之前申请成为首席原告 [1][3] - 成为首席原告可以代表其他集体成员参与诉讼 [3] - 即使不成为首席原告,投资者也可以作为隐性成员参与,并有权获得潜在的赔偿 [3]

文章核心观点 - 帕拉贡28公司(Paragon 28, Inc.)的财务报表存在错报 [1][4] - 帕拉贡28公司内部控制存在缺陷,有时会低估内部控制问题的严重程度 [1][4] - 由于上述问题,公司对自身业务、运营和前景的陈述存在重大虚假或误导性 [4] 根据相关目录分别进行总结 公司情况 - 帕拉贡28公司是一家上市公司,股票代码为FNA,在纽约证券交易所交易 [1] - 投资者在2023年5月5日至2024年8月8日期间购买了公司普通股或期权,可能有资格获得赔偿 [1] 诉讼进展 - 罗森律师事务所代表投资者提起了证券集体诉讼 [1][2] - 投资者如果希望担任首席原告,必须在2024年11月29日之前向法院提出申请 [2] 罗森律师事务所介绍 - 罗森律师事务所是一家专注于证券集体诉讼和股东衍生诉讼的全球性投资者权益律师事务所 [3] - 该所在2017年被ISS证券集体诉讼服务评为证券集体诉讼和和解数量第一 [3] - 该所自2013年以来一直位列前四名,并为投资者收回了数亿美元的赔偿 [3] - 2019年单年就为投资者赢得了4.38亿美元的和解金 [3] - 该所的多名律师受到了Lawdragon和Super Lawyers的认可 [3]

文章核心观点 - 公司Outset Medical被指在2022年8月1日至2024年8月7日期间做出了虚假或误导性陈述,未能披露公司Tablo产品的相关信息[1][4] - 公司Tablo产品未获得美国FDA批准用于连续性肾脏替代治疗,公司可能需要提交额外的510(k)申请[4] - 公司存在停止销售Tablo产品直至获得FDA批准的重大风险[4] - 公司缺乏执行Tablo销售增长的销售团队和流程,收入增长将受到不利影响[4] 公司相关 - 公司Outset Medical的Tablo产品未获得FDA批准用于连续性肾脏替代治疗[4] - 公司可能需要提交额外的510(k)申请[4] - 公司存在停止销售Tablo产品直至获得FDA批准的重大风险[4] - 公司缺乏执行Tablo销售增长的销售团队和流程,收入增长将受到不利影响[4] 行业相关 - 无相关内容